Autologous Stem Cell Transplantation using a Modified TAM Conditioning Regimen for Clinically Aggressive Non-Hodgkin’s Lymphoma

참고문헌 (25)

1. "Armitage JO. Treatment of non-Hodgkin's lymphoma. N Engl J Med. 1993;328", pp.1023~30
2. Philip T, "Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma", 333, pp.1540~1545 (1995)
3. Vose JM, "Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry", 19, pp.406~413 (2001)
4. Haioun C, "Survival benefit of high-dose therapy in poor- risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymph-omes de l'Adulte study", 18, pp.3025~3030 (2000)
5. Salar A, "Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: the role of preparative regimens", 27, pp.405~412 (2001)
6. Gutierrez-Delgado F, "Autologous stem cell transplantation for non-Hodgkin's lymphoma: comparison of radiation-based and chemotherapy-only preparative regimens", 28, pp.455~461 (2001)
7. Appelbaum FR, "et al. Treatment of malignant lymphoma in 100 patients with chemotherapy", pp.1340~7
8. Stein RS, "Intensified preparative regimens and autologous transplantation in refractory or relapsed intermediate grade non-Hodgkin's lymphoma", 25, pp.257~262 (2000)
9. Weaver CH, "and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma. J Clin Oncol. 1994;12", pp.2559~66, Press O
10. Bordigoni P, "Total body irradiation-high-dose cytosine arabinoside and melphalan followed by allogeneic bone marrow transplantation from HLA-identical siblings in the treatment of children with acute lymphoblastic leukaemia after relapse while receiving chemotherapy: a Societe Francaise de Greffe de Moelle study", 102, pp.656~665 (1998)
11. Dai QY, "Antileukemic and long-term effects of two regimens with or without TBI in allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia", 34, pp.667~673 (2004)
12. Chopra R, "et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood. 1993;81", pp.1137~45, Linch DC
13. Caballero MD, "BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors", 20, pp.451~458 (1997)
14. Kim HJ, "Autologous stem cell transplantation using modified TAM or combination of triple-alkylating agents conditioning regimens as one of the post-remission treatments in patients with adult acute myeloid leukemia in first complete remission", 34, pp.215~220 (2004)
15. Jaffe ES, "World Health Organization" (2001), Lyon Oxford
16. "A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329", pp.987~94
17. Cheson BD, "Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas", 17, pp.1244~ (1999)
18. Bearman SI, "et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol. 1988;6", pp.1562~8
19. Trad S, "Fatal progressive systemic sclerosis following autologous stem cell transplantation and high-dose chemotherapy", 44, pp.951~953 (2005)
20. Aristei C, "Total-body irradiation in the conditioning regimens for autologous stem cell transplantation in lymphoproliferative diseases", 4, pp.386~397 (1999)
21. Kalaycio M, "Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia", 24, pp.3604~3610 (2006)
22. Stockerl-Goldstein KE, "Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma", 2, pp.76~85 (1996)
23. Crawford SW, "Critical care and resporiatory failure", pp.712~722 (1999), Boston: Blackwell Scientific
24. Press OW, "Phase I", II trial of iodine-131-tositumomab (anti- CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas, 2000, pp.96, 2934~2942
25. Nademanee A, "A phase 1", 2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgikin's lymphoma, 2005, pp.106, 2896~2902

관련 논문AI추천